Sellas Life Sciences Group
SLS · NASDAQ
$11.98+$1.49 (+14.20%)TodayMarket closed ·
Prev close $10.49
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 22.3% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$0.05
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.0455 | -$0.05 | −9.9% |
| Q1 FY26 | -$0.0404 | -$0.05 | −23.8% |
| Q4 FY25 | -$0.0657 | -$0.05 | +23.9% |
| Q3 FY25 | -$0.0667 | -$0.06 | +10.0% |
| Q2 FY25 | -$0.0832 | -$0.07 | +15.9% |
| Q1 FY25 | -$0.1061 | -$0.07 | +34.0% |
| Q4 FY24 | -$0.1084 | -$0.08 | +26.2% |
| Q3 FY24 | -$0.1313 | -$0.10 | +23.8% |
Earnings calls
- Special Call - SELLAS Life Sciences Group, Inc.
- SELLAS Life Sciences Group, Inc., 2025 Guidance/Update Call, Jan 08, 2025
- Special Call - SELLAS Life Sciences Group, Inc.
- Special Call - SELLAS Life Sciences Group, Inc.
- Special Call - SELLAS Life Sciences Group, Inc.
- Special Call - SELLAS Life Sciences Group, Inc.
- Special Call - SELLAS Life Sciences Group, Inc.
- Special Call - SELLAS Life Sciences Group, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.